Overview of Pericon

Property	Description
Active ingredient	Econazole Nitrate, Triamcinolone Acetonide
Form	Cream or Ointment
Pharmacological class	Topical Anti-infective and Corticosteroid Combination
Common use	Relieving inflammation and treating associated fungal growth
Origin	Synthetic

What Type of Combination Medicine is Pericon?

Pericon is a dual-action combination medicinal product classified as a topical anti-infective and corticosteroid, designed exclusively for application to the skin via the cutaneous route of administration. This formulation is clinically recognized for providing simultaneous treatment of fungal proliferation and symptomatic inflammation, a structure which is distinct from monotherapies. The medicine is typically supplied as a cream or an ointment, which are the standard topical dosage forms used for external application.

Understanding the Active Ingredients: Econazole and Triamcinolone Acetonide

Pericon contains the two key synthetic active pharmaceutical ingredients: Econazole (as Econazole Nitrate) and Triamcinolone Acetonide. Econazole is designated as an Azole Antifungal agent, working by interfering with the synthesis of fungal cell membranes. The second component, Triamcinolone Acetonide, is a potent glucocorticoid within the topical corticosteroid drug class. This specific composition is commonly utilized in various equivalent generic formulations, which underscores its established therapeutic profile. This pairing ensures both the microbial element and the resulting symptomatic reaction are addressed concurrently.

General Purpose: Targeting Infection and Inflammation

The general purpose of this medicine is to provide relief from acute symptoms of skin inflammation while simultaneously controlling the microbial cause. The drug delivers powerful anti-inflammatory and anti-pruritic (anti-itching) effects, reducing the severe swelling and irritation often associated with compromised skin. This comprehensive dual mechanism allows the medication to stabilize the irritated state of the skin and facilitate recovery in situations where redness and intense itching are complicated by the presence of a susceptible fungal issue.

Regulatory References

Physiology, Glucocorticoids - StatPearls - NCBI Bookshelf

What side effects are possible with Pericon?

Possible side effects and safety information

The safety profile for this combination medicine, containing Econazole Nitrate and Triamcinolone Acetonide, is based on adverse reactions documented in official government regulatory sources for its active components.

Adverse Reaction Scope

The most frequently reported adverse reactions, classified as Common in regulatory documents for the Econazole component, are local skin effects occurring at the application site. These include a burning sensation, itching, stinging, and erythema (redness).

Adverse effects stemming from the corticosteroid component are primarily categorized as Skin and Subcutaneous Tissue Disorders (e.g., dryness, irritation, folliculitis, skin atrophy) and may occur infrequently, with increased risk noted under specific conditions.

Systemic Safety and Constraints

Systemic effects are a concern due to the absorption of the Triamcinolone Acetonide. Serious adverse reactions documented in regulatory documents are generally classified under Endocrine System Disorders and include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome.

Duration- and Exposure-Related Patterns: The risk for systemic effects and serious local reactions like skin atrophy and striae is associated with prolonged use, application over large body surface areas, or the use of occlusive dressings.

Population-Specific Considerations: Regulatory safety notes indicate that pediatric patients may exhibit greater susceptibility to systemic toxicity, including the risk of HPA axis suppression and growth retardation, due to their higher ratio of skin surface area to body weight.

Regulatory Constraints: The medicine is contraindicated in individuals with a known hypersensitivity to any of its components. If a co-existing infection does not respond to appropriate treatment, the corticosteroid component should be discontinued.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define potential overdose scenarios based on two distinct exposure routes: accidental ingestion and excessive topical absorption.

Documented Overdose Presentations

Exposure Route	Documented Manifestations
Accidental Ingestion (Econazole Component)	Symptoms may include dizziness, headache, nausea, and loss of coordination [NIH MedlinePlus].
Excessive Topical Use (Corticosteroid Component)	Systemic absorption may result in manifestations of Cushing's syndrome or Hypothalamic-Pituitary-Adrenal (HPA) axis suppression [FDA Prescribing Information].

Regulatory Guidance for Emergency Actions

Accidental oral ingestion of the product requires the user to seek immediate medical attention and contact a doctor or Poison Center [Official Safety Documents]. In cases of ingestion, official regulatory guidance explicitly states that vomiting must not be induced.

For potential corticosteroid over-absorption linked to prolonged use or large-area application, the risk of HPA axis suppression is documented as a severe outcome, which is typically reversible. Regulatory documents mandate that patients be evaluated periodically using specific laboratory tests, such as the ACTH stimulation test, to monitor this systemic effect [FDA Prescribing Information]. Pediatric patients are noted to be at increased risk of systemic toxicity, with documented signs of adrenal suppression including retarded linear growth.

Therapeutic Uses of Pericon

What Pericon Treats: Main Uses and Benefits

Pericon is generally used to address conditions involving inflammatory or irritative processes on the skin where a fungal element is present, such as eczematous mycoses and inflamed forms of tinea (like athlete's foot and jock itch). The corticosteroid component is applied to help relieve the itching, redness, and inflammation associated with various skin conditions. The combination generally assists with addressing both the fungal element and the associated inflammation, which is relevant for managing specific symptom patterns.

The cream is commonly applied in specific contexts, such as inflammatory intertrigo and certain types of diaper dermatitis. It is considered relevant in clinical settings marked by symptoms that create noticeable physiological strain, including intense pruritus, erythema, and edema. Its application offers symptomatic relief that may assist with helping patients cope more steadily with these difficult manifestations.

“This medication is primarily used for managing symptoms that interfere with daily comfort and when short-term symptomatic assistance is needed.”

Used during these phases when symptoms become more noticeable, it helps maintain a sense of stability and provides targeted assistance in symptom stabilization in challenging anatomical regions.

Quick Fact: Relief for Intense Itching (Pruritus) The combination is relevant for easing symptoms when fungal infections are complicated by acute, distressing manifestations like persistent pruritus and pronounced swelling.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Pericon (Econazole Nitrate/Triamcinolone Acetonide) is authorized for use primarily in adults and adolescents who do not present with specific contraindications. Regulatory guidance strictly defines the groups who must not use the medicine, largely due to the potent corticosteroid component.

Eligibility Scope	Official Regulatory Classification
Populations Contraindicated	Individuals with known hypersensitivity to any component of the cream; patients with primary cutaneous viral infections (e.g., Herpes Simplex, Varicella), tuberculosis cutis, syphilitic skin lesions, Rosacea, or Perioral dermatitis at the site of application.
Age-Related Restrictions	Safety and effectiveness are generally not established in younger pediatric patients. Infants and children are highly susceptible to systemic absorption, which carries a risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.
Pregnancy/Lactation Status	Not recommended for use during pregnancy, especially extensively or for prolonged periods. Use is conditional, requiring the potential benefit to justify the risk. Application to the breast area is prohibited during lactation.
Eligibility-Related Restrictions	Use is strictly limited and not recommended on large body surface areas, under occlusive dressings, or on open wounds/ulcerated skin.

What should I know about interactions with other medicines?

This section outlines officially documented interaction patterns involving the components of Pericon, strictly as defined in government regulatory labeling. The primary concerns stem from the potential for minimal systemic absorption of the active ingredients and subsequent pharmacokinetic interactions.

Interaction Entity

Official Regulatory Description

Anticoagulants

Co-administration with Coumarin anticoagulants (e.g., Warfarin) may result in the enhancement of the anticoagulant effect due to the Econazole component’s potential for CYP450 enzyme inhibition. Regulatory guidance specifies that close monitoring of prothrombin time and International Normalized Ratio (INR) is necessary during co-treatment.

CYP3A Inhibitors

Potent inhibitors of the CYP3A enzyme, such as cobicistat-containing products and ritonavir, are expected to reduce the clearance of the Triamcinolone Acetonide component. This pharmacokinetic interaction increases the risk of systemic corticosteroid side-effects, leading to the official restriction that such combinations should be avoided unless the benefits are determined to outweigh the risk.

Interaction-Context Constraints

The likelihood of these systemic interactions becoming clinically significant is linked to the extent of component absorption. The official interaction risk is therefore designated as heightened when the product is applied to a large body surface area, used under occlusion (such as bandages), or applied to the genital area, as these conditions facilitate increased systemic absorption.

Mechanism of Action

Selective VDR Activation and Gene Regulation

Pericon's core action is the selective activation of the Vitamin D Receptor (VDR), a nuclear receptor found in cells of the parathyroid glands, kidney, and intestine. This receptor binding initiates a molecular cascade where the activated drug-VDR complex translocates to the nucleus and suppresses the transcription of the Parathyroid Hormone (PTH) gene. This primary effect is central to the adjustment of hormonal signaling pathways associated with mineral homeostasis.

Reduction of Parathyroid Hormone (PTH) Secretion

The gene regulation cascade leads directly to a significant reduction in the synthesis and release of PTH from the parathyroid glands. This results in an alteration in the body's endocrine signaling system. Lowered circulating PTH levels reduce the signal strength within the pathways associated with bone turnover and calcium and phosphate dynamics.

Adjustment of Systemic Mineral Homeostasis

The reduction in PTH, combined with Pericon's VDR-mediated effects on the gut and kidney, alters the physiological set point for calcium and phosphate balance. This mechanism engages the feedback loops of mineral homeostasis, resulting in an adjustment of their set points.

Dosage and Administration Information

How to Use Pericon: Official Administration Guidelines

Pericon, a combination of Econazole Nitrate and Triamcinolone Acetonide, is administered strictly through the topical route for application directly to the skin. The medicine is supplied as a cream or ointment containing the combination of Econazole Nitrate 1% and Triamcinolone Acetonide 0.1%.

Official Usage Protocol

The established regimen requires the application of a thin film of the product sufficient to cover the entire affected area. This is typically done twice daily, once in the morning and once in the evening. The cream must be gently rubbed into the skin following the preparation steps of cleaning and drying the application site prior to use.

Feature	Official Instruction
Frequency	Twice Daily (Morning and Evening)
Dosing	Apply a thin film over the entire affected area
Duration	Typically 14 days or up to two to four weeks for certain conditions. The full course should be completed.

Administration Constraints and Population Rules

Administration of Pericon includes specific procedural constraints to ensure proper use. The treated skin area must not be covered or wrapped with an occlusive dressing or tight fitting material unless explicitly instructed by a healthcare provider. This non-occlusive condition is also critical when applying the product in the diaper area of infants.

Regarding high-level population rules, use in pediatric patients is subject to a strict time limitation and should not normally exceed 5 days due to the potential effects of the corticosteroid component. If no clinical improvement is observed after the completion of the prescribed duration, the diagnosis must be formally re-evaluated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pericon

This overview describes the types of clinical evaluations and research that have examined the combination of Econazole Nitrate and Triamcinolone Acetonide, focusing on the available evidence without providing clinical advice or treatment instructions.

Evidence for Use in Inflamed Superficial Skin Infections

The clinical evaluation for managing inflamed superficial skin infections, such as ringworm (tinea) and other common fungal issues, primarily relies on short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time in adult patients diagnosed with mild-to-moderate fungal infections.

Studies monitored global changes in skin appearance, measured specific outcomes linked to inflammatory or irritative states, and assessed the clearance of the fungal issue. Studies monitored high rates of mycological clearance in the observed populations when assessed immediately after the treatment period. Research highlights changes measured during the study period, with observed rapid initial changes in outcomes related to physical discomfort associated with the flare-up.

However, evidence remains limited regarding the durability of these findings. Because follow-up durations were limited, long-term effects are not fully established.

Investigating Long-Term Outcomes and Recurrence

The available research primarily focuses on short-term symptom changes that occur over a defined time interval, usually 2 to 4 weeks. Long-term effects are not fully established, as follow-up durations were limited across the majority of the major trials.

The evidence suggests that while rapid symptomatic changes were observed in some studies, findings help contextualize how patients reported their experience over defined time intervals. There is limited information available that systematically tracks the condition over many months after treatment cessation to assess the potential for recurrence or how the skin maintains stability.

What is Still Uncertain About the Research for Pericon

Research is ongoing in dermatology, and studies suggest the existing evidence highlights what is known and what is still uncertain about this formulation.

Comparative Evidence: Comparative evidence is lacking to definitively establish how the combination performs against the corticosteroid component alone for symptom evaluation in many contexts.
Study Scope: The study results reflect the specific conditions under which they were conducted. Findings were mixed in older literature regarding certain patient types, and evidence quality varies across studies where only observational data is available.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Pericon (FAQ)

Q: How quickly should I expect Pericon to start working?

A: Studies examining the use of Pericon have shown that rapid initial changes were observed in outcomes related to the physical discomfort of the inflammation. These changes were observed within the defined time intervals of the studies. Official information indicates these rapid changes relate to improvements in local symptoms.

Q: Can Pericon cause weight gain or weight loss?

A: Reported side effects associated with the corticosteroid component, Triamcinolone Acetonide, include weight gain or unexplained weight loss. The risk of these systemic effects is related to the degree of absorption of the medicine through the skin into the body.

Q: Is it normal to feel a bit dizzy when first starting Pericon?

A: Dizziness has been reported as a systemic adverse effect linked to the Triamcinolone Acetonide component. This effect is usually associated with higher systemic exposure, such as when the medicine is used over a large area or for extended periods.

Q: Does taking Pericon affect birth control pills?

A: Official drug interaction information notes that female hormones, such as those in oral contraceptives, may enhance the systemic effects of corticosteroids. For a topical medicine like Pericon, the clinical significance of this interaction depends on how much of the drug is absorbed into the bloodstream.

Q: Can Pericon be used by children, and if so, what are the restrictions?

A: Official guidance notes that use in pediatric patients is subject to strict time limitations due to the potential for systemic effects of the corticosteroid component. Treatment should not normally exceed 5 days in this population. Children may have a higher ratio of skin surface area to body weight, which increases the risk of absorption.

Q: Does Pericon affect sleep patterns?

A: Sleep disturbance, including insomnia or sleeplessness, has been reported as an uncommon psychiatric side effect. This is associated with the systemic action of the Triamcinolone Acetonide component.

Q: Is the tablet scored so it can be split, according to the manufacturer?

A: Pericon is supplied exclusively as a cream or ointment, which are topical dosage forms for application to the skin. The medicine is not a tablet and is designed for topical application as a film.

Q: What is the main difference between Pericon and [a common similar drug]?

A: Pericon is a dual-action combination medicinal product containing two active ingredients: the antifungal agent Econazole Nitrate and the corticosteroid Triamcinolone Acetonide. The key distinction of this product is its composition, which is designed to address both microbial issues and inflammation concurrently.

Q: If I miss a dose of Pericon, what should I do?

A: Regulatory documents describe the general guidance for a missed dose, which involves applying it as soon as it is remembered. The guidance specifies that if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued.

Q: Can Pericon be taken by people who are sensitive to certain ingredients?

A: Regulatory labeling states that the medicine is contraindicated in individuals who have a known hypersensitivity to any of its components. This includes both the active ingredients and the inactive excipients in the cream or ointment formulation.

Q: What happens if I stop taking Pericon suddenly?

A: Sudden cessation, particularly after prolonged use or application over a large body surface area, may carry a theoretical risk of withdrawal-related effects. This is linked to the potential for the corticosteroid component to cause suppression of the body's natural hormone production (HPA axis suppression).

Q: Are there any dietary restrictions mentioned for Pericon?

A: Due to its topical route of administration, regulatory documents for this medicine do not specify any required dietary restrictions or special instructions related to food consumption.

Q: Are the initial side effects of Pericon temporary?

A: The most frequently reported adverse reactions, such as burning, itching, and stinging, are local skin effects at the application site. These effects may diminish or resolve with continued use, and are typically evaluated upon completion of the prescribed duration.

Q: How does Pericon get eliminated from the body?

A: The systemic portion of the corticosteroid component, Triamcinolone Acetonide, is primarily eliminated from the body. Regulatory documents describe this process as excretion in the urine and faeces.

Q: Does Pericon have a risk of dependence or withdrawal symptoms?

A: Drug dependence is reported as an uncommon psychiatric side effect associated with the systemic action of the Triamcinolone Acetonide component. This is often linked to the potential for HPA axis suppression.

Q: Are there different strengths of Pericon available?

A: The official regulatory description of the combination product specifies that it is supplied as a cream or ointment containing Econazole Nitrate 1% and Triamcinolone Acetonide 0.1%.

Q: What category is Pericon listed under for safety in breastfeeding?

A: Official information from the NIH indicates that the risk to a nursing infant from topical use is considered low. This assessment is based on the minimal systemic absorption of the active ingredients when applied to the skin.

Q: What is the common misunderstanding people have about Pericon's use?

A: A common point of clarification is understanding that the medicine is a dual-action product. It contains both an antifungal agent and a corticosteroid, distinguishing it from single-ingredient treatments that address only the infection or only the inflammation.

Q: Is there a particular time of day that is best for taking Pericon?

A: The official usage protocol specifies application twice daily. This established regimen requires application once in the morning and once in the evening, aligning with a consistent application schedule.

Q: What are the official clinical expectations regarding the drug's effect?

A: The clinical expectations described in the research overview include the monitoring of mycological clearance (the elimination of the fungal issue). Additionally, studies observe rapid initial changes in outcomes related to the physical discomfort of the skin inflammation.

How should Pericon be stored and disposed of?

Official Storage Conditions

Pericon (Econazole Nitrate/Triamcinolone Acetonide) must be stored under specific environmental constraints to maintain its quality, strength, and purity, as directed in regulatory labeling.

Temperature: The product must be stored at a temperature that does not exceed 30°C (86°F) and must not be frozen, as freezing can compromise the cream or ointment formulation.
Protection: The container must be kept in a way that protects the contents from light and excessive moisture. To prevent accidents, the medicine must be stored out of the sight and reach of children.
Stability: If a specific 'use-by' period is defined after first opening the tube (e.g., 28 days), the medicine must be discarded after this time, regardless of the expiration date printed on the packaging.

Disposal Instructions

All unused or expired medicine must be disposed of in accordance with local governmental regulations. Disposal should follow established pharmaceutical take-back programs or community collection points, and the product should not be discarded into wastewater or standard household waste unless explicitly instructed by a regulatory authority.

Pericon